C4 Therapeutics (CCCC) Free Cash Flow (2019 - 2026)

C4 Therapeutics' Free Cash Flow history runs 8 years deep, the most recent figure standing at -$30.0 million for Q1 2026.

• In Q1 2026, Free Cash Flow rose 9.92% year-over-year to -$30.0 million; the TTM figure through Mar 2026 stood at -$96.0 million (down 19.25% YoY), while the FY2025 annual figure was -$99.3 million, down 51.98% from the prior year.
• Free Cash Flow was -$30.0 million for Q1 2026 at C4 Therapeutics, down from -$22.2 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$5.0 million in Q2 2024 to a low of -$33.3 million in Q1 2023.
• Historically, Free Cash Flow has averaged -$24.0 million across 5 years, with a median of -$25.3 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Free Cash Flow soared 73.79% in 2024, then sank 147.66% in 2025.
• A 5-year view of Free Cash Flow shows it stood at -$28.1 million in 2022, then gained by 20.14% to -$22.5 million in 2023, then advanced by 20.23% to -$17.9 million in 2024, then decreased by 23.58% to -$22.2 million in 2025, then plunged by 35.32% to -$30.0 million in 2026.
• The last three Free Cash Flow figures came in at -$30.0 million (Q1 2026), -$22.2 million (Q4 2025), and -$31.5 million (Q3 2025), per Business Quant data.